LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Nonsteroid management of residual ocular surface disease on dupilumab (ROSDD),☆☆☆

Photo by homajob from unsplash

https://doi.org/10.1016/j.ijwd.2019.08.007 2352-6475/ 2019 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). q Financial Disclosure(s): The author(s)… Click to show full abstract

https://doi.org/10.1016/j.ijwd.2019.08.007 2352-6475/ 2019 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). q Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Dr. Murase has participated in advisory boards for Genzyme/Sanofi, Dermira, and UCB, participated in disease statement management talks for Regeneron and UCB, and provided dermatologic consulting services for Ferndale and UpToDate. qq No human subjects were included in this study. No animals were used in this study. ⇑ Corresponding author. E-mail address: [email protected] (J.E. Murase). Jodie Raffi, BA , Raagini Suresh, BS , Timothy Berger, MD , Harvey Fishman, MD, PhD , Jenny E. Murase, MD a,d,⇑

Keywords: nonsteroid management; management; management residual; surface disease; residual ocular; ocular surface

Journal Title: International Journal of Women's Dermatology
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.